Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,129,012
  • Shares Outstanding, K 47,003
  • Annual Sales, $ 186,370 K
  • Annual Income, $ -163,420 K
  • 60-Month Beta 1.14
  • Price/Sales 6.16
  • Price/Cash Flow N/A
  • Price/Book 4.53
Trade MIRM with:

Options Overview Details

View History
  • Implied Volatility 73.26% ( -2.97%)
  • Historical Volatility 36.78%
  • IV Percentile 58%
  • IV Rank 51.75%
  • IV High 104.11% on 03/12/24
  • IV Low 40.17% on 08/08/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 1,911
  • Open Int (30-Day) 2,239

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 6
  • High Estimate 0.05
  • Low Estimate -0.73
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +53.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.14 +5.83%
on 04/25/24
26.61 -7.97%
on 04/05/24
-1.65 (-6.31%)
since 03/25/24
3-Month
23.14 +5.83%
on 04/25/24
30.23 -18.99%
on 03/01/24
-1.72 (-6.56%)
since 01/25/24
52-Week
23.14 +5.83%
on 04/25/24
35.56 -31.13%
on 12/15/23
-2.27 (-8.48%)
since 04/25/23

Most Recent Stories

More News
United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023

Stocks that traded heavily or had substantial price changes on Monday: United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall

VLO : 167.13 (+0.08%)
ADBE : 473.44 (-0.77%)
MIRM : 24.49 (+1.96%)
DOOR : 131.75 (+0.11%)
NIO : 4.13 (-0.48%)
ILMN : 121.05 (-1.48%)
Why Shares of Travere Therapeutics Are Slumping Thursday

A mixed trial could hurt a kidney drug's chances of full approval.

MIRM : 24.49 (+1.96%)
TVTX : 5.39 (-1.10%)
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 16.67% and 3.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

MIRM : 24.49 (+1.96%)
YMAB : 14.84 (-2.94%)
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.

MIRM : 24.49 (+1.96%)
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -17.65% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ADPT : 2.61 (+0.38%)
MIRM : 24.49 (+1.96%)
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBIV : 0.5994 (+1.59%)
MIRM : 24.49 (+1.96%)
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first...

MIRM : 24.49 (+1.96%)
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?

IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

IDYA : 38.62 (-3.09%)
MIRM : 24.49 (+1.96%)
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”)...

MIRM : 24.49 (+1.96%)
American Airlines, Emerson Electric fall; Triton, Chart rise

Stocks that traded heavily or had substantial price changes Wednesday: American Airlines, Emerson Electric fall; Triton, Chart rise

MIRM : 24.49 (+1.96%)
TRTN : 79.55 (-4.10%)
EMR : 109.60 (-0.02%)
TH.TO : 1.80 (-2.70%)
NATI : 59.98 (unch)
NCMI : 4.59 (-0.86%)
GTLS : 152.00 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 26.51
2nd Resistance Point 25.56
1st Resistance Point 25.03
Last Price 24.49
1st Support Level 23.55
2nd Support Level 22.60
3rd Support Level 22.07

See More

52-Week High 35.56
Fibonacci 61.8% 30.82
Fibonacci 50% 29.35
Fibonacci 38.2% 27.88
Last Price 24.49
52-Week Low 23.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar